Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
No biomarker
Cancer:
Bladder Cancer
Drug:
Keytruda (pembrolizumab)
(
PD1 inhibitor
) +
Padcev (enfortumab vedotin-ejfv)
(
Microtubule inhibitor
,
Nectin-4-targeted antibody-drug conjugate
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
NCCN
Published date:
04/25/2023
Excerpt:
Bladder Cancerā¦.Cisplatin ineligible, first-line therapy for locally advanced or metastatic diseaseā¦.Preferred regimen:...pembrolizumab and enfortumab vedotin-ejfv
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login